Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study)

Werner Klein, Arnd Buchwald, W. Stewart Hillis, Scott Monrad, Ginés Sanz, Alexander G.G. Turpie, Jan Van Der Meer, Eric Olaisson, Sven Undeland, Karin Ludwig

Research output: Contribution to journalArticlepeer-review

54 Scopus citations


The safety and efficacy of weight-adjusted, low-molecular-weight heparin (dalteparin) was compared with that of unfractionated heparin during 6 days of treatment in 1,482 patients with unstable angina or non-Q-wave myocardial infarction. Dalteparin, at a lower dose, was compared with placebo during the following 39 days. No significant outcome difference was found between the 2 treatment regimens in the unblinded phase (days 1-6). Between days 6-45 the rates of death, myocardial infarction, and recurrence of angina were comparable between the active treatment and placebo groups. The results suggest that twice-daily administration of subcutaneous dalteparin may be an effective and safe alternative to unfractionated heparin during the acute phase of unstable coronary artery disease. Prolonged treatment with dalteparin at a lower once daily dose did not confer any additional benefit over aspirin (75-165 mg) alone.

Original languageEnglish (US)
Pages (from-to)30E-34E
JournalAmerican Journal of Cardiology
Issue number5 A
StatePublished - Sep 4 1997
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study)'. Together they form a unique fingerprint.

Cite this